Responsiveness of PROMIS and Patient Health Questionnaire (PHQ) Depression Scales in three clinical trials

Abstract

Background The PROMIS depression scales are reliable and valid measures that have extensive normative data in general population samples. However, less is known about how responsive they are to detect change in clinical settings and how their responsiveness compares to legacy measures. The purpose of this study was to assess and compare the responsiveness of the PROMIS and Patient Health Questionnaire (PHQ) depression scales in three separate samples. Methods We used data from three clinical trials (two in patients with chronic pain and one in stroke survivors) totaling 651 participants. At both baseline and follow-up, participants completed four PROMIS depression fixed-length scales as well as legacy measures: Patient Health Questionnaire 9-item and 2-item scales (PHQ-9 and PHQ-2) and the SF-36 Mental Health scale. We measured global ratings of depression change, both prospectively and retrospectively, as anchors to classify patients as improved, unchanged, or worsened. Responsiveness was assessed with standardized response means, statistical tests comparing change groups, and area-under-curve analysis. Results The PROMIS depression and legacy scales had generally comparable responsiveness. Moreover, the four PROMIS depression scales of varying lengths were similarly responsive. In general, measures performed better in detecting depression improvement than depression worsening. For all measures, responsiveness varied based on the study sample and on whether depression improved or worsened. Conclusions Both PROMIS and PHQ depression scales are brief public domain measures that are responsive (i.e., sensitive to change) and thus appropriate as outcome measures in research as well as for monitoring treatment in clinical practice. Trial registration ClinicalTrials.gov ID: NCT01236521, NCT01583985, NCT01507688

Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors

“…Regression to the mean is more likely when initial fatigue scores are high. Finally, scales for other symptoms have also proven better at detecting improvement than worsening [ 42 , 74 , 75 ].…”

Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer

“…Most opioid renewals require a written prescription, which offers an ideal opportunity to repeat depression screening using valid, brief assessments. Numerous options are available to screen for depression and mood disturbance in chronic pain [ 30 – 33 ]. The PHQ-2 [ 34 ], a two-item depression screener, is the shortest screening instrument and as accurate as the longer PHQ-9 [ 35 ] for detecting depression in patients with cancer [ 30 ].…”

Association of Depression with Sperm Quality: a Multicentre Cross-Sectional Study in China During the COVID-19 Pandemic

“…Participants completed a mental scale assessment based on their psychological feelings according to their mental state in the last two weeks while completing the semen collection. On the basis of previous studies, a score of 5-9 was de ned as mild depression, and a score of 10 or greater was de ned as severe depressive symptoms [20,21]. The reliability and validity of the simpli ed Chinese version of PHQ-9 have been demonstrated [22].…”